Every cancer patient deserves the right treatment
for their individual form of cancer.
New The power of precision, For Every Oncologist, Today
With IndiTreat, 2cureX makes the testing of chemotherapeutic agents on patient-derived microtumors an operational reality.
The latest news around the IndiTreat® clinical trial in colorectal cancer patients that met its primary endpoint.
For over 2 decades, testing cancer treatments on microtumors rather than on the patient has been on the horizon. With IndiTreat®, 2cureX makes microtumor testing an operational reality to serve you and your cancer clinic.
IndiTreat CE IVD is available today for identifying effective chemotherapies of certain forms of colorectal cancer if a biopsy is feasible. Ask your doctor if it is possible to consider IndiTreat for your cancer.
2cureX Newsletter May’21
Press Releases Regulatory
Teckningsoptioner av serie TO1 tecknades till cirka 96,75 procent och 2cureX AB tillförs cirka 31,40 MSEK
Warrants of series TO1 were subscribed to approximately 96.75 percent and 2cureX AB receives approximately SEK 31.40 million.
2cureX unlocks the power of precision oncology (Biostock Article)
Get notified on mail, when news or press release is posted on our website